Ultragenyx Pharmaceutical Inc v. Navinta LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Ultragenyx Pharmaceutical Inc. (Delaware)
  • Defendant: Navinta LLC (New Jersey); Aurobindo Pharma Limited (India); Aurobindo Pharma USA, Inc. (Delaware); Esjay Pharma Private Limited (India); and Esjay Pharma LLC (Florida)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-03585, D.N.J., 04/03/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Navinta LLC being a New Jersey company residing in the district; Aurobindo USA, Inc. and Esjay Pharma LLC having regular and established places of business in the district; and their foreign parent companies, Aurobindo Pharma Limited and Esjay Pharma Private Limited, being subject to suit in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' filing of Abbreviated New Drug Applications (ANDAs) to market generic versions of Plaintiff's DOJOLVI® (triheptanoin) oral liquid constitutes an act of infringement of a patent covering a high-purity liquid formulation of the drug.
• Technical Context: The technology concerns pharmaceutical-grade liquid compositions of triheptanoin, a triglyceride-based therapy used for treating rare metabolic conditions known as long-chain fatty acid oxidation disorders (LC-FAOD).
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of their respective ANDAs to the U.S. Food and Drug Administration (FDA). Each ANDA included a "Paragraph IV certification" asserting that U.S. Patent No. 12,551,461 is invalid, unenforceable, or will not be infringed by the proposed generic products. The complaint notes a prior, pending action against the same defendants related to a different patent but the same drug product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,551,461 - Compositions of triglycerides and uses thereof

• Patent Identification: U.S. Patent No. 12,551,461, "Compositions of triglycerides and uses thereof," issued February 17, 2026 (the "'461 Patent").

The Invention Explained

• Problem Addressed: The patent describes problems associated with the then-current liquid (oil) dosage form of triglyceride drugs like triheptanoin ʼ461 Patent, col. 1:26-28 These problems include difficulty in administration due to low miscibility with food and drinks, as well as significant gastrointestinal side effects such as gastric upset, spasms, emesis, and diarrhea upon administration ʼ461 Patent, col. 1:30-40 These tolerability issues can be a "dose-limiting toxicity," potentially reducing the treatment's effectiveness ʼ461 Patent, col. 1:40-44
• The Patented Solution: While the patent's background and summary sections extensively discuss creating a solid composition by adsorbing the triglyceride oil onto a solid carrier to improve tolerability ʼ461 Patent, abstract ʼ461 Patent, col. 1:50-54, the asserted claims are directed to a specific, high-purity liquid formulation. The claims define a liquid triheptanoin oil composition by its high purity (>98%) and by specific, narrow ranges or undetectable levels of certain impurities, including diheptanoate, hexano-diheptanoate, glycerol, and monoheptanoate ʼ461 Patent, claim 1 The specification provides detailed tables specifying the characteristics of this pharmaceutical-grade triheptanoin, distinguishing it from lower-purity "food grade" versions ʼ461 Patent, col. 14:56-59 ʼ461 Patent, col. 15:1-12
• Technical Importance: The claimed invention provides a liquid pharmaceutical composition with a defined and controlled purity profile, which may be relevant for ensuring safety, efficacy, and consistency in treating patients with rare metabolic disorders ʼ461 Patent, col. 1:40-44
  No probative visual evidence provided in complaint.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 against all Defendants Compl. ¶103 Compl. ¶112 Compl. ¶121
• The essential elements of independent claim 1 are:
  • A pharmaceutical composition comprising an active ingredient, diheptanoate, and hexano-diheptanoate,
  • wherein the active ingredient is in the form of triheptanoin oil;
  • wherein the triheptanoin oil has a purity greater than 98%;
  • wherein the composition comprises 0.01% to 1.5% diheptanoate by weight;
  • wherein the composition comprises 0.01% to 1.0% hexano-diheptanoate by weight;
  • wherein glycerol is undetectable in the composition;
  • wherein monoheptanoate is undetectable in the composition;
  • wherein the composition comprises no more than 0.2% water by weight; and
  • wherein the composition is a liquid composition for oral administration to a human.
• The complaint does not explicitly reserve the right to assert dependent claims, but alleges infringement of "one or more claims" Compl. ¶103

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are the Defendants' proposed generic versions of triheptanoin oral liquid, 100% w/w, as described in their respective ANDAs: Navinta ANDA No. 219480, Aurobindo ANDA No. 219711, and Esjay ANDA No. 219512 Compl. ¶1

Functionality and Market Context

• The Defendants' products are described as "triheptanoin oral liquid" intended to be generic versions of Plaintiff's FDA-approved drug, DOJOLVI® Compl. ¶1 Compl. ¶76 Compl. ¶86 Compl. ¶96 The complaint alleges that by filing their ANDAs, the Defendants have represented to the FDA that their products are bioequivalent to DOJOLVI® Compl. ¶78 Compl. ¶88 Compl. ¶98
• The accused products are intended for the same therapeutic use as DOJOLVI®, which is the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) Compl. ¶15 Compl. ¶75 Compl. ¶85 Compl. ¶95

IV. Analysis of Infringement Allegations

The complaint does not contain a detailed, element-by-element infringement analysis or a claim chart exhibit. The infringement allegation is predicated on the Defendants' submission of ANDAs for products that are purported to be bioequivalent generic versions of Plaintiff's DOJOLVI® product. The core theory is that a product bioequivalent to DOJOLVI® will necessarily meet the specific compositional limitations of the asserted claims of the '461 Patent.

'461 Patent Infringement Allegations

Identified Points of Contention

• Factual/Infringement Question: The central dispute will likely be whether the Defendants' proposed generic products, as defined in their ANDAs, actually meet every limitation of Claim 1. The Defendants asserted non-infringement in their Paragraph IV certifications Compl. ¶77 Compl. ¶87 Compl. ¶94, suggesting they may argue their products are formulated to have a different purity or impurity profile that falls outside the specific ranges claimed.
• Validity Question: The Defendants' Paragraph IV certifications also assert that the '461 Patent is invalid Compl. ¶77 Compl. ¶87 Compl. ¶94 A potential line of argument could be that achieving the specific purity and impurity profile recited in Claim 1 would have been obvious to a person of ordinary skill in the art of pharmaceutical manufacturing and purification at the time of the invention.

V. Key Claim Terms for Construction

• The Term: "purity greater than 98%"

• Context and Importance: This term is foundational to the claim, as it distinguishes the invention from prior art "food grade" triheptanoin ʼ461 Patent, col. 14:56-59 The infringement and validity analyses will depend on how this purity level is defined and measured, specifically which substances are considered impurities for the calculation.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party might argue the term should be given its plain and ordinary meaning in the field of pharmaceutical chemistry, referring to the weight percentage of the triheptanoin molecule itself relative to all other substances in the oil.
  • Evidence for a Narrower Interpretation: The specification provides detailed examples of purity analysis, listing specific impurities like diheptanoate and hexano-diheptanoate (ʼ461 Patent, col. 17:12-42, Table 4). A party could argue that "purity" is implicitly defined by the levels of the specific impurities discussed in the patent, as measured by the analytical methods referenced (e.g., Ph. Eur. 2.4.22 method C) ʼ461 Patent, col. 16:32-62

• The Term: "undetectable"

• Context and Importance: Claim 1 requires that both glycerol and monoheptanoate be "undetectable." This negative limitation is inherently tied to the sensitivity of the analytical method used. The dispute will center on what standard of detection defines this term.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party could argue for an absolute interpretation, meaning the composition must be completely free of the substance, regardless of the measurement technique.
  • Evidence for a Narrower Interpretation: The specification references standard pharmaceutical testing methods, such as those from the European Pharmacopoeia (Ph. Eur.) ʼ461 Patent, col. 15:32-65 A party will likely argue that "undetectable" means below the limit of detection of the relevant, industry-standard analytical method at the time of the invention. Example data in Table 4 explicitly state these components are "not detectable," linking the claim term to a specific analytical outcome ʼ461 Patent, col. 17:12-42

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement against all Defendants. The inducement allegations are based on the premise that, upon approval, the Defendants will encourage direct infringement by marketing their products for the same patented use as DOJOLVI® Compl. ¶104 Compl. ¶113 Compl. ¶122 Contributory infringement is alleged on the basis that the ANDA products are especially adapted for an infringing use and have no substantial non-infringing use Compl. ¶105 Compl. ¶114 Compl. ¶123
• Willful Infringement: The prayer for relief for each Defendant seeks a judgment of willful and deliberate infringement Compl. p. 26, ¶(g) Compl. p. 28, ¶(g) Compl. p. 29, ¶(g) The factual basis for willfulness appears to be the Defendants' filing of their ANDAs with Paragraph IV certifications, an act which Plaintiff alleges was done with knowledge of the '461 Patent.

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of compositional identity: does the precise chemical formulation of the Defendants' proposed generic products, as detailed in their confidential ANDA submissions, fall within the specific, narrow ranges for purity and impurities recited in Claim 1? The case will likely depend on detailed chemical analysis and expert testimony comparing the accused products to the claimed profile.
• A key legal question will be one of claim construction: how will the court define the term "undetectable"? The resolution of this term-whether it means an absolute absence of a substance or below the detection limit of a specific analytical technique-will be critical in determining both infringement and validity.
• The case may also hinge on a question of obviousness: could a person of ordinary skill in the art of pharmaceutical manufacturing have arrived at the claimed high-purity triheptanoin composition through routine purification and optimization techniques, or does the specific profile represent a non-obvious inventive step?